Follow us on Twitter
twitter icon@FreshPatents


Angioedema patents

      

This page is updated frequently with new Angioedema-related patent applications.




 Therapeutic inhibitory compounds patent thumbnailTherapeutic inhibitory compounds
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like..
Lifesci Pharmaceuticals, Inc.


 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema patent thumbnailPlasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.. .
Dyax Corp.


 Treatment of hereditary angioedema with c1 inhibitor patent thumbnailTreatment of hereditary angioedema with c1 inhibitor
A method for treating acute attacks of hereditary angioedema (hae) whereby a first does and a second dose of a recombinant c1 esterase inhibitor is administered intravenously to the patient, each dose at 50 iu/kg body weight of the patient and wherein the first and second doses are administered within a 24 hour period. The recombinant c1 esterase inhibitor has an amino acid sequence identical to the amino acid sequence of human plasma-derived c1 esterase inhibitor and a modified carbohydrate structure as compared to the human plasma-derived c1 esterase inhibitor.
Santarus, Inc.


 Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema patent thumbnailAdeno-associated virus mediated delivery of c1ei as a therapy for angioedema
This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human c1 esterase inhibitor or factor xii. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema..
Cornell University


 Compositions and methods for inhibiting gene expression of factor xii patent thumbnailCompositions and methods for inhibiting gene expression of factor xii
Rna interference (rnai) triggers for inhibiting the expression of factor xii (f12) gene through the mechanism of rna interference are described. Pharmaceutical compositions comprising one or more f12 rnai triggers together with one or more excipients capable of delivering the rnai trigger(s) to a liver cell in vivo are also described.
Arrowhead Madison Inc.


 Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema patent thumbnailTherapy for chronic idiopathic urticaria, anaphylaxis and angioedema
Methods for treating or relieving at least one symptom of urticarial disorders including chronic idiopathic urticaria, angioedema, and anaphylaxis, or a combination of these disorders in a mammal, including humans. The method comprises administering to the mammal a therapeutically effective amount of pramipexole, dexpramipexole or pharmaceutically acceptable salts thereof..

 Therapeutic inhibitory compounds patent thumbnailTherapeutic inhibitory compounds
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like..
Lifesci Pharmaceuticals, Inc.


 Methods of treating b2-bradykinin receptor mediated angioedema patent thumbnailMethods of treating b2-bradykinin receptor mediated angioedema
Methods of treating b2-bradykinin receptor mediated angioedema in a subject by administering a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof. Oral formulations containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof for the treatment of b2-bradykinin receptor mediated angioedema.
Shire Human Genetic Therapies, Inc.


 Evaluation and treatment of bradykinin-mediated disorders patent thumbnailEvaluation and treatment of bradykinin-mediated disorders
The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pkal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (kma), or other diseases mediated by pkal useful in the evaluation and treatment.
Dyax Corp.


 Evaluation, assays and treatment of pkal-mediated disorders patent thumbnailEvaluation, assays and treatment of pkal-mediated disorders
The invention provides assay methods of detecting plasma protease ci inhibitor (c1-inh) that binds plasma kallikrein, factor xii, or both, and uses thereof for identifying subjects at risk for or suffering from a pkal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (kma), or other diseases mediated by pkal useful in the evaluation and treatment..
Dyax Corp.


Pharmaceutical composition and functional food comprising natural extracts for preventing or treating diabetic complications or angiodema

The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of hedera helix leaves and coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema further containing an extract of rheum palmatum, puerariae radix, ginkgo leaves, cassiae semen, blueberry, bilberry, raspberry, or grape seeds as an active ingredient, in addition to the mixed extract of hedera helix leaves and coptis chinensis..
Korea Institute Of Oriental Medicine

(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.. .
Bayer Pharma Aktiengesellschaft

Methods for modulating factor 12 expression

Disclosed herein are methods for decreasing factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to factor 12 include hereditary angioedema (hae).

Methods for modulating kallikrein (klkb1) expression

Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (hae).

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Provided herein are peptide inhibitors of the interaction between end binding protein 3 (eb3) and inositol 1,4,5-trisphosphate receptor type 3 (ip3r3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion..

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Provided herein are peptide inhibitors of the interaction between end binding protein 3 (eb3) and inositol 1,4,5-trisphosphate receptor type 3 (ip3r3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion..

Diagnosis and treatment of angioedema

The present patent application relates to a method for diagnosing angioedema with a gain-of-function mutation of kinin formation, and for determining the amount of bk or des-arg9 -bk antagonist required for halting the effects of angioedema, from a plasma sample of a patient. The invention also relates to a kit for said determination..



Angioedema topics:
  • Angioedema
  • Sudden Infant Death
  • Bronchopulmonary
  • Allergic Reaction
  • Antihistamine
  • Sudden Infant Death Syndrome
  • Therapeutical
  • Staurosporin
  • Staurosporine
  • Multiple Sclerosis
  • Dermatitis
  • Aspergillosis
  • Effective Dose
  • Food Allergy
  • Allergic Rhinitis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Angioedema for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Angioedema with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2018

    file did exist - 1178

    1 - 1 - 24